TICOVAC (tick-borne encephalitis vaccine)
TICK-BORNE ENCEPHALITIS VACCINE · TICK-BORNE ENCEPHALITIS VACCINATION
Parke-Davis Pfizer
Drug class
Tick-Borne Encephalitis Vaccine
Tick-borne encephalitis vaccine is an immunobiological drug class composed of inactivated, whole-virus viral vaccines designed to stimulate active immunity against the tick-borne encephalitis virus. Read more about Tick-Borne Encephalitis Vaccine
1 drugs in this class 1 manufacturers
Drugs in Tick-Borne Encephalitis Vaccine
Filter & compare in the drug finder →
Opens the drug finder with Tick-Borne Encephalitis Vaccine preselected. Add indication or manufacturer filters there.
Tick-borne encephalitis vaccine is an immunobiological drug class composed of inactivated, whole-virus viral vaccines designed to stimulate active immunity against the tick-borne encephalitis virus.
It works by exposing the host immune system to purified, inactivated viral antigens, eliciting neutralizing antibody titers against viral surface glycoproteins to prevent infection upon subsequent tick-borne or alimentary exposure.
The primary clinical indication for this class is active immunization to prevent central nervous system infections, meningitis, and encephalitis caused by tick-borne encephalitis virus in individuals residing in, traveling to, or working in endemic areas.
-
fda.gov
Tick-borne encephalitis vaccine is an immunobiological drug class composed of inactivated, whole-virus viral vaccines designed to stimulate active immunity against the tick-borne encephalitis virus
-
cdc.gov
Tick-borne encephalitis vaccine is an immunobiological drug class composed of inactivated, whole-virus viral vaccines designed to stimulate active immunity against the tick-borne encephalitis virus
-
fda.gov
It works by exposing the host immune system to purified, inactivated viral antigens, eliciting neutralizing antibody titers against viral surface glycoproteins to prevent infection upon subsequent tick-borne or alimentary exposure
-
fda.gov
It works by exposing the host immune system to purified, inactivated viral antigens, eliciting neutralizing antibody titers against viral surface glycoproteins to prevent infection upon subsequent tick-borne or alimentary exposure
-
fda.gov
The primary clinical indication for this class is active immunization to prevent central nervous system infections, meningitis, and encephalitis caused by tick-borne encephalitis virus in individuals residing in, traveling to, or working in endemic areas
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.